Treace Medical Concepts, Inc. announced that its SpeedPlate(TM) Rapid Compression Implant System ("SpeedPlate(TM)") has received 510(k) clearance from the FDA to be used for fracture fixation, osteotomy fixation, and joint arthrodesis of the foot and ankle. The SpeedPlate(TM) System was designed for rapid delivery of titanium compression implants, serving as enabling fixation technology with Treace's new Micro-Lapiplasty(R) instrumentation which allows the patented Lapiplasty(R) procedure to be performed through small, 2cm incisions. The SpeedPlate(TM) implant platform also serves as a versatile addition to the Company's fixation portfolio, with broad compatibility with conventional Lapiplasty(R), Lapiplasty(R) Mini-Incision(TM), and Adductoplasty(R) procedures/systems.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.4 USD | +0.97% | -6.31% | -18.43% |
Mar. 25 | Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction | MT |
Feb. 27 | Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.43% | 638M | |
+73.17% | 12.34B | |
-18.74% | 7.96B | |
+16.15% | 7.16B | |
+4.81% | 5.72B | |
+5.99% | 5.03B | |
+27.07% | 4.35B | |
-21.67% | 3.99B | |
-40.82% | 2.21B | |
+1.49% | 2.01B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Receives FDA 510(k) Clearance for SpeedPlate(TM) Rapid Compression Implant Technology